NCT06121401 (IOLANTHE) is a Phase 4 clinical trial of Olaparib in Carcinoma, Ovarian Epithelial, sponsored by Mario Negri Institute for Pharmacological Research.

Who is sponsoring NCT06121401?

NCT06121401 is sponsored by Mario Negri Institute for Pharmacological Research.

What drugs are being tested in NCT06121401?

Interventions in NCT06121401: Olaparib, Bevacizumab.

What condition does NCT06121401 study?

NCT06121401 studies Carcinoma, Ovarian Epithelial.

Is NCT06121401 still recruiting?

NCT06121401 is currently active, enrolled. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT06121401: IOLANTHE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Active, enrolled Phase 4 Last updated 17 September 2025

What this trial tests

Phase 4 trial testing Olaparib in Carcinoma, Ovarian Epithelial in 190 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 September 2023

Primary endpoint
15 March 2027

15 September 2027

Quick facts

Lead sponsor	Mario Negri Institute for Pharmacological Research
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	190
Start date	15 September 2023
Primary completion	15 March 2027
Estimated completion	15 September 2027
Sites	2 locations across Italy

Drugs / interventions tested

Olaparib (olaparib) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Carcinoma, Ovarian Epithelial — all drugs for Carcinoma, Ovarian Epithelial →

Sponsor

Mario Negri Institute for Pharmacological Research

Who can join

Adults 18 to 75, female only, with Carcinoma, Ovarian Epithelial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective, phase IV, multi-centre clinical trial is to to define the proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive who will be treated at first line with olaparib in combination with bevacizumab as maintenance and to describe their clinical and demographic characteristics. Other primary objective is to confirm, in a setting close to clinical practice, the efficacy of olaparib concomitant with bevacizumab as maintenance treatment after first-line chemotherapy in patients with advanced high grade EOC HRD-positive and who have received bevacizumab in combination with chemotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.
Beltrame L, Mannarino L, Sergi A, Velle A, et al · · 2025 · cited 3× · PMID 40393377 · DOI 10.1016/j.esmoop.2025.105060
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.
Philips TJ, Erickson BK, Thomas SN. · · 2024 · cited 1× · PMID 39839766 · DOI 10.3389/fonc.2024.1503107
Targeting Tumor Stroma: Current Challenges and Future Directions.
Wang S, Hu H, Zeng W, Qin L, et al · · 2026 · PMID 42125068 · DOI 10.1002/mco2.70763
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.
Paracchini L, Velle A, Di Gennaro P, Mannarino L, et al · · 2026 · PMID 41747586 · DOI 10.1016/j.esmoop.2026.106087

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other recruiting trials for Carcinoma, Ovarian Epithelial

Currently open trials in the same condition.

NCT05544929 — A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers · Phase 1 · active not recruiting
NCT05601700 — Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) · Phase 3 · recruiting
NCT05116189 — Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-34 · Phase 3 · active not recruiting
NCT04807166 — Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer · Phase 2 · active not recruiting
NCT04660929 — CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting

Other Mario Negri Institute for Pharmacological Research trials

Trials by the same sponsor.

NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07331103 — RESOLving INflammation Through Diet for Health (RESOLVIN) · NA · recruiting
NCT06994468 — Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy · NA · completed
NCT07111624 — A New Crowding Indicator in the Emergency Department · not yet recruiting
NCT07021118 — Mild TBI in the Emergency Department · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06121401 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mario Negri Institute for Pharmacological Research
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06121401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing